The rise of copyright’s blockbuster initially sparked a boom for major pharmaceutical companies, nevertheless recent changes present a uncertain outlook for those considering a stake. Generic alternatives are reducing revenue, and persistent legal battles add additional difficulty to the situation. While some companies could still see gains from